Navigation Links
Bioassociate Reiterated PT on RedHill Biopharma Following Q2 Report
Date:8/20/2013

to buy any security in any jurisdiction where such an offer would be illegal. Bioassociate is not soliciting any action based upon this material. It does not take into account the particular investment objectives, financial situation, risk profile or other needs of individual investors. Before acting on any advice or recommendation in this material, an investor should consider whether it is suitable for his/her particular circumstances and, if necessary, seek professional advice. The report is based upon information that we consider reliable, but we do not represent that it is accurate or complete, and it should be relied upon as such. Opinions expressed are Bioassociate's current opinions as of the date appearing on this material only; such opinions are subject to change without notice. RedHilll is a client of Bioassociate and is paying Bioassociate a cash fee for Bioassociate's services, which include the preparation of equity research and valuation reports. The research report is based on public information and on information provided by RedHill, which according to RedHill is available publicly.  

Please read each report's full disclosures and analyst background on Bioassociate website, http://www.bioassociate.com, before investing. Bioassociate is not a registered investment adviser or broker-dealer.

The research report described in this press release contains forward-looking data subject to risks and uncertainties that could cause actual results to differ materially from those projected. These forward-looking data represent Bioassociate's judgment as of the date of this release. Bioassociate disclaims, however, any intent or obligation to update this forward-looking data.

Contact:
info@bioassociate.com
+972-3-541-5050


'/>"/>
SOURCE Bioassociate
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Bioassociate Announces Initiation of Coverage on Oramed Pharmaceuticals, Inc.
2. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
3. PDL BioPharma Announces Adjusted Conversion Rates for Its Convertible Notes
4. CeNeRx BioPharma Completes $4.85 Million Financing
5. PDL BioPharma Completes Regular Quarterly Dividend Payment
6. PAREXEL Introduces Executive Briefing Series on Proven Practices to Assist Emerging and Mid-size Biopharma in Achieving Better Outcomes
7. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
8. Keryx Biopharmaceuticals to Present at JP Morgans 30th Annual Healthcare Conference
9. HealthCare Institute of New Jersey Releases 2011 Biopharmaceutical and Medical Technology Economic Impact Data
10. Sigma-Aldrich to Acquire BioReliance; Extending Its Reach into Biopharmaceutical Testing and Services
11. Galien Foundation Announces 2012 Awards Program For Best Biopharmaceutical Products and Best Medical Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Antonio, TX (PRWEB) August 29, 2014 ... and ISO 13485:2003 certified, GAMP® 5 compliant imaging ... awarded an international Phase II clinical trial to ... lymphoma. , Throughout this trial, Intrinsic Imaging will ... not limited to, protocol and charter development, site ...
(Date:8/28/2014)... “This kit has an improved extraction efficiency and ... 150 ppb,” said Mark Tess, PhD, Mycotoxin Product Manager for ... owners and USDA-GIPSA inspection agencies that have a need to ... place in a matter of minutes with nothing but our ... feed and grain before accepting it, but they no longer ...
(Date:8/28/2014)... August 28, 2014 The ability for ... culture that will allow individuals to perform at the ... important for employers looking to compete in this post–recession ... embracing this trend, as the sector increasingly focuses on ... company, which will have real results on the organization's ...
(Date:8/28/2014)... Aug. 28, 2014  Armetheon, Inc. ( www.armetheon.com ... mid- to late-stage cardiovascular drug candidates, today announced ... first round of financing. The Series A round ... Bioventures with participation from investors that included Atheneos ... Dr. Larry Hsu , the founder of ...
Breaking Biology Technology:Intrinsic Imaging Awarded Phase II Clinical Trial to Assess New Treatment for Non-Hodgkin’s Lymphoma 2Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 2Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 3Armetheon Completes $7.0 Million Series A Financing 2Armetheon Completes $7.0 Million Series A Financing 3
... China, FORT LAUDERDALE, Fla., Sept. 5 ... pioneer in laser,optical breast cancer imaging systems, has ... Tianjin Medical University,s Cancer Institute and,Hospital, the largest ... http://www.newscom.com/cgi-bin/prnh/20040412/IMDSLOGO ) Research at the Cancer ...
... EDMONTON, Sept. 5 /PRNewswire-FirstCall/ - Biomira Inc. (Nasdaq: ... of three-year survival results,from a randomized Phase II ... lung cancer (NSCLC). The results suggest that Stimuvax,combined ... benefits to,patients with unresectable stage IIIB NSCLC who ...
... FRANCISCO, Calif., Sept. 5 Hyperion,Therapeutics, a biopharmaceutical ... and hepatology therapies for the,treatment of Urea Cycle ... $40 million Series B financing. Leading the round ... Partners and,NEA, all of Menlo Park, CA. WRF ...
Cached Biology Technology:Largest Asian Cancer Hospital to Evaluate New CT Laser Breast Imaging System 2Largest Asian Cancer Hospital to Evaluate New CT Laser Breast Imaging System 3Stimuvax(R) Phase II data highlight three-year survival results for patients with non-small cell lung cancer 2Stimuvax(R) Phase II data highlight three-year survival results for patients with non-small cell lung cancer 3Stimuvax(R) Phase II data highlight three-year survival results for patients with non-small cell lung cancer 4Hyperion Therapeutics Secures $40 Million In Series B Round 2
(Date:8/28/2014)... than traditional cigarettes, but still release toxins into ... USC. , Scientists studying secondhand smoke from e-cigarettes ... harmful particles, with close-to-zero exposure to organic carcinogens. ... in second-hand e-cigarette smoke were found to be ... levels of polycyclic aromatic hydrocarbons cancer-causing organic ...
(Date:8/28/2014)... groups and clinicians is critical to the development ... of Georgia research. , A qualitative study of ... that role models for successful breastfeeding help positively ... "Mothers who received that support are more likely ... Alex Anderson, an associate professor in the College ...
(Date:8/28/2014)... complex systems. Their infrastructure equipment requires ancillary sub-systems ... to supply fuel, and ICT systems for control ... is interconnected with a wider network and they ... scientists has studied various aspects of inter-network dependencies, ... in EPJ B by Gaihua Fu from Newcastle ...
Breaking Biology News(10 mins):Second-hand e-cig smoke compared to regular cigarette smoke 2Breastfeeding study shows need for effective peer counseling programs 2Inter-dependent networks stress test 2
... by Dr. Ann F. Jacobson, associate professor in Kent ... may initially choose to postpone but ultimately undergo total ... patient education before and after the procedure. ... pre-and post operative experiences with total knee replacement surgery, ...
... release is available in Spanish . , A ... (USA) and Nakai (China), among others, have deciphered for the first ... to the cover of the last issue of the prestigious journal ... to the group of Molecular Genetics of the Department of ...
... fund four faculty research projects for spring 2008. ... a number of excellent proposals submitted in response ... for the program is administered by the OSU ... by royalties from OSU-licensed technologies. These funded projects ...
Cached Biology News:Research examines factors in delaying or declining total knee replacement surgery 2Scientists decipher fruit tree genome for the first time 2Scientists decipher fruit tree genome for the first time 3OSU technologies funded for development 2OSU technologies funded for development 3
... Maxi MB (for aqueous, other low volatility ... systems respond to specific applications of molecular ... concentration of heat-labile samples. The RC systems ... cold traps and a wide selection of ...
... Acid Resistant SpeedVac Model SPD131DDA , Our ... SPD131DDA is designed to handle the rigors and ... slim design, digital display, dual independent timers, an ... chamber and vapor pathway. , , Adjustable ...
...
For absolute protein quantification. 4 peptides in 5 vials x 2 nmol per peptide...
Biology Products: